Camber Pharmaceuticals continues to strengthen its range of treatment options with the introduction of Nilotinib Capsules [nye-LOE-ti-nib].
Nilotinib is indicated for the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) for pediatric patients greater than or equal to 1 year of age and adults, based on various stages of disease diagnosis, disease progression, and previous treatment results.
For complete indications, click here.
Nilotinib capsules are available in 150 mg and 200 mg strengths, each supplied in 4 blister packs of 28 capsules.
To learn more about this product, visit: www.camberpharma.com/nilotinib
